Ticker Reports for February 26th
Viking Therapeutics: The High-Stakes Weight Loss Contender
The pharmaceutical industry is currently witnessing a historic gold rush surrounding obesity treatments. While industry titans like Novo Nordisk (NYSE: NVO) and Eli Lilly (NYSE: LLY) dominate the headlines and the pharmacy shelves, the market remains hungry for a third player to disrupt the status quo. Supply shortages and high prices have created a massive opening for agile competitors, and Viking Therapeutics (NASDAQ: VKTX) has emerged as the most advanced, clinical-stage challenger in the field.
Trading around $34 as of late February, Viking represents a distinct alternative for investors. It is not a stable, dividend-paying giant—it is a high-beta growth play. This means the stock offers significantly higher volatility than the broader sector, but also higher potential upside. Viking stands at a crossroads, balancing the potential of a massive buyout premium against the operational risks of challenging the world’s largest drugmakers on their own turf.
The Weapon of Choice: Speed and Differentiation
Viking’s primary asset is VK2735, a dual agonist that targets GLP-1 and GIP receptors. This mechanism mirrors the biology behind some of the most effective treatments currently available, such as Zepbound. However, Viking is advancing it at a pace that sets the company apart from most clinical-stage biotechs and strengthens the case for real commercial demand.
The company recently achieved a major milestone by completing enrollment for its Phase 3 VANQUISH-1 trial in obesity. The trial exceeded its target of 4,500 patients ahead of schedule.
This speed is a strong indicator of two things: high patient demand for alternative treatments and investigator enthusiasm for Viking's specific molecule. Additionally, the VANQUISH-2 trial, focusing on obesity in patients with Type 2 diabetes, is nearing full enrollment in the first quarter of 2026.
However, the true differentiator may not be the injection, but the tablet. Viking is advancing an oral formulation of VK2735, which demonstrated up to 12.2% weight loss in Phase 2 trials. Phase 3 trials for the oral version are scheduled to begin in the third quarter of 2026.
Most current treatments require weekly injections, which can be a barrier for many patients. Viking is one of the few companies developing a dual agonist in both injectable and oral forms. This allows for a flexible treatment paradigm:
- Induction: A patient could potentially induce rapid weight loss with an injection.
- Maintenance: The patient could then switch to a daily pill to maintain that weight loss.
This flexibility allows patients to stay within the Viking ecosystem throughout their treatment, a decisive competitive advantage over single-format therapies.
Built to Buy or Built to Last?
Wall Street has long speculated that Viking is a prime takeover target for a major pharmaceutical company looking to buy its way into the obesity sector. However, Viking’s management appears to be executing a dual-track strategy. They are positioning the company to be an attractive acquisition while simultaneously building the infrastructure to launch independently.
This intent is visible in their recent hiring. In January 2026, Viking appointed Neil Aubuchon as Chief Commercial Officer. Aubuchon is a veteran of the sector, having spent nearly 17 years at Eli Lilly (NYSE: LLY), a direct competitor. His decision to leave an industry leader to join Viking suggests a strong belief in the pipeline's commercial viability.
Furthermore, Viking has signed a comprehensive agreement with CordenPharma to support the commercial-scale manufacturing of VK2735. This is a critical strategic move. The current market leaders, Lilly and Novo, have struggled profoundly with manufacturing shortages. Small biotechnology companies often fail not because their drug doesn't work, but because they cannot make enough of it.
By securing a top-tier manufacturing partner and hiring experienced commercial leadership, Viking removes significant execution risk. This strategy creates leverage. If a suitor wants to acquire Viking, they are not just buying a patent; they are buying a turnkey pharmaceutical division. This forces potential acquirers to pay a premium, knowing that Viking is fully capable of competing alone if a deal does not materialize.
Burning Cash to Build Value
Growth in the biotech sector is expensive, and Viking’s financials reflect the cost of its ambition. In its fourth-quarter earnings report released in February 2026, the company reported a loss of $1.38 per share, missing analyst estimates of a $0.89 loss. This wider loss was driven primarily by Research and Development (R&D) expenses, which jumped to $345 million for the fiscal year, up from $101.6 million the previous year.
For investors, it is crucial to interpret this spending correctly. The capital is not being wasted; it is being invested in massive, simultaneous Phase 3 clinical trials. To support this, Viking maintains a fortress balance sheet with specific strengths:
- Liquidity: The company holds $706 million in cash, cash equivalents, and short-term investments.
- Runway: This liquidity ensures the company is fully funded through its major data readouts in 2026, removing the immediate fear of a dilutive capital raise.
Despite the clinical progress, the market remains skeptical. As of late January 2026, short interest in Viking stood at approximately 26 million shares, representing roughly 24.04% of the float. This high level of betting against the stock creates a volatile coiled spring dynamic.
Short sellers are betting the stock price will go down. However, if Viking delivers positive news, such as the completion of VANQUISH-2 enrollment or a successful IND filing for its new Amylin agonist, short sellers may be forced to cover their positions rapidly. This buying pressure can drive the stock price up regardless of broader market conditions, a phenomenon known as a short squeeze.
The disparity between market sentiment and analyst expectations is stark. While the stock trades in the mid-$30s, the average analyst price target sits at $87.80. This gap implies a potential upside of over 150% if the company successfully executes its roadmap.
The Final Weigh-In: Risk Meets Reward
Viking Therapeutics represents a high-stakes opportunity in one of the most lucrative sectors of modern medicine. It offers a front-row seat to the obesity drug revolution, with the potential to become a major player either through a lucrative buyout or a successful independent launch.
The company has successfully transitioned from early-stage research to late-stage execution. With the VANQUISH-1 trial fully enrolled and the oral program heading toward Phase 3, the clinical path is clear. Meanwhile, the dual-track strategy of securing manufacturing capacity and commercial leadership provides a safety net against the failure of a buyout offer.
However, the path is volatile. The company’s stock moves aggressively in response to news from its larger competitors, and its high short interest guarantees a bumpy ride. For investors with a tolerance for risk, the company’s cash reserves and advanced clinical data provide a compelling thesis. The next immediate catalyst to watch is the completion of enrollment in the VANQUISH-2 diabetes trial, expected later this quarter.
After PSKY's $31 Bid, Could Netlfix Exit the WBD Bidding War?
The Warner Bros. Discovery (NASDAQ: WBD) acquisition saga took another dramatic turn that the company itself may not have seen coming. After Netflix (NASDAQ: NFLX) agreed to a seven-day waiver period, which accelerated Paramount Skydance’s (NASDAQ: PSKY) bidding process, PSKY has upped its offer. And, for the first time, Warner Bros. is indicating that Paramount’s bid could win out.
Paramount Sweetens the Pot With $31 Bid, Stronger Equity Backing
When Warner Bros. and Netflix gave Paramount one week to submit its best bid, WBD didn’t sound as if it expected much to change. In announcing the waiver, WBD management said, “To be clear, our Board has not determined that your proposal is reasonably likely to result in a transaction that is superior to the Netflix merger." WBD added, “We continue to recommend and remain fully committed to our transaction with Netflix." It seems that thinking may now be growing stale.
After the conclusion of the waiver period, Paramount increased its headline offer to $31 per share, up from its previous $30 bid. After receiving this, WBD’s rhetoric took a clear turn. The company said that Paramount's revised offer could reasonably be expected to lead to a "Company Superior Proposal." In short, WBD is circling back to PSKY, believing its offer could be better than Netflix’s.
However, the $1 price increase was far from the biggest factor that shifted the entertainment giant’s perspective.
Beyond this, Paramount made several key concessions designed to address WBD’s concerns about deal certainty and financing risk.
Most critically, Paramount agreed to contribute additional equity funding, as needed, to satisfy PSKY’s lenders should debt markets or the fundamentals of the combined company deteriorate. Essentially, Paramount’s owners, specifically Oracle (NYSE: ORCL) founder Larry Ellison, will pay for WBD in cash should debt funding dry up. This directly addressed one of WBD’s biggest concerns, as the financing certainty around PSKY’s previous offer was inferior to that of Netflix’s.
Netflix’s bid also includes debt financing. However, Netflix has nearly $9.1 billion in cash and equivalents on its balance sheet. It also generated $9.46 billion in free cash flow over the last 12 months. At Paramount, these figures stand at just $2.66 billion and $308 million, respectively. Netflix’s vastly superior cash position and production capacity made it much less likely that lenders would withdraw their funds. But, with a net worth of over $190 billion, Larry Ellison’s backing is the great equalizer for Paramount.
Netflix Shares Rally as Investors Anticipate a Retreat
Notably, Warner Bros. has not actually determined that Paramount’s offer is superior to Netflix’s yet. WBD’s Board “continues to recommend in favor of the Netflix transaction and is not withdrawing or modifying its recommendation.”
It is currently evaluating whether the Paramount deal is superior. Should it decide this is the case, Netflix will have four days to negotiate a counteroffer.
In a telling reaction, Netflix shares popped approximately 6% after Paramount provided its updated bid. As Paramount’s chances of winning WBD have now increased, the market is clearly indicating that it believes Netflix not buying WBD is what’s best for the company. Investors are now assigning a larger probability to Netflix walking away from the deal, rather than trying to beat out Paramount’s offer.
Prior to this latest reversal, Netflix shares had fallen around 20% since announcing the WBD acquisition. This shows that investors did not view the deal as a good use of capital. It also may have signaled that Netflix internally questioned its ability to maintain robust organic growth.
WBD Going Forward: Will Netflix Back Out or Pony Up?
For WBD shareholders, the possibility that Netflix will walk away from the bidding war is now a greater threat. This is important, as the prospect that NFLX and PSKY will push their offers higher has been the main driver of WBD stock. Getting a better deal from Paramount is all fine and dandy, but the absence of a continued bidding war will limit further upside.
At the same time, it’s possible that Netflix counters, and a bidding war commences once again, leading to further gains. Still, the jolt in Netflix's stock indicates that investors view this as a lower-probability outcome. And at the end of the day, the deal still needs regulatory approval for investors to receive the $31 price. It’s still possible that regulators don’t approve a Netflix or Paramount deal. Frankly, it’s difficult to say what might happen next.
With WBD now trading near $29 per share, further gains may only be incremental compared to what the stock has already achieved. Meanwhile, Netflix backing away and the Paramount deal falling through for whatever reason could lead to considerable downside. Overall, these factors make it worth considering whether it's time to take the money and run with WBD.
Have $500? Invest in Elon's AI Masterplan
Have $500? Invest in Elon's AI Masterplan
Workday, Seriously, It's Time to Buy This SaaS Leader
Workday’s (NASDAQ: WDAY) stock price decline did not end with its Q4 2025 earnings report; it continued to long-term lows, creating an even more attractive opportunity for investors. While guidance fell short of the consensus and AI disruption fears linger, the bar was set high, the miss is slim, guidance is solid, and disruption, well, it may not happen quite the way the market expects.
AI-first companies may try to move into Workday’s territory by turning models into full HR/finance software.
But incumbents like Workday are embedding AI into their existing platforms. And, because they’re already deeply integrated into enterprise workflows and data, they may be harder to displace than the market fears.
The analyst response to the earnings news was unfavorable. A downgrade to Hold by Jefferies and numerous price target reductions came with commentary highlighting the abrupt CEO change mentioned in the release, as co-founder and Executive Chairman Aneel Bhusri is returning to the helm to navigate the company through its next phase.
Workday Accelerates Growth and Profitability in Q4 2025
Workday had a solid quarter in Q4, with revenue growth accelerating sequentially to 14.5%. The $2.53 billion in revenue outpaced MarketBeat’s reported consensus by 40 basis points, driven by strength in subscriptions, up 15.7% YOY, and the strength carried through to the bottom line.
Margin news was equally strong with the GAAP and adjusted operating margins widening by several hundred basis points. The 420 bps improvement in adjusted operating margin led to a 32% increase in operating income and 28% increase in adjusted earnings, 650 bps better than expected.
Guidance was the sticking point, as the Q1 and full-year 2026 revenue forecasts fell short of consensus. However, the company forecasts 13% topline growth in Q1, 12.5% for the year, and an adjusted operating margin that remains strong. In this environment, price action may reset but is unlikely to stay down long. As it is, WDAY’s consensus target is about 100% above its critical support levels, while even the low-end range offers some upside.
Institutional Support and Share Buybacks Underpin WDAY Rebound Outlook
Two factors underpinning WDAY’s potential for a rebound are its capital returns and institutional support. Capital returns consist entirely of share repurchases, which are reliable and reduce the share count annually. The 2025 repurchase activity reduced the count by approximately 0.4%, a level sufficient to improve shareholder leverage, and institutions are buying into it.
Institutional data reveals this group owns more than 90% of the stock and has been accumulating on a quarterly basis for 7 consecutive quarters, including the first two months of Q1 2026. The balance in Q1 2026 is only about $1.15 bought for each $1 sold, but is trending bullish, and the ramp in buying to offset a ramp in selling suggests this group will keep buying despite the “tepid” guidance.
Workday’s balance sheet reflects the impact of its capital return, acquisitions, and growth investments, but no red flags are raised. The cash balance is healthy, flat YOY, and the decrease in current assets is offset by an increase in total. Liabilities are also up, causing equity to contract, but leverage remains light at two times cash and under 0.5 times equity, providing an easy path for debt reduction and improving equity as 2026 progresses.
Catalyst for Workday Stock: Yes, They Exist
Catalysts for Workday in 2026 include continued growth, improving cash flow, and the potential for outperformance relative to Q1 and full-year guidance. The company noted caution in the outlook, citing macroeconomic uncertainty and a longer timeline to deal closing. The likely outcome is that Workday outperforms quarterly throughout the year, leading to guidance improvement and a rebound in analyst and market sentiment. The question now is whether the stock will rebound from the new lows, which is likely. Trading near $115, WDAY is in a zone not fathomed since the depths of the COVID-19 panic.
The Biggest IPO Ever: Claim Your Stake Today
The Biggest IPO Ever: Claim Your Stake Today
MarketBeat Media, LLC dba TickerReport
345 N Reid Place, Suite 620, Sioux Falls, SD 57103.